Vifor Pharma Group Reports Continued Growth in H1 2020
Net sales and EBITDA continued to grow in H1 2020 despite challenging market conditions due to COVID-19 Ferinject®/ Injectafer® demand impacted by global COVID-19 restrictions Sustained growth in nephrology supported by dialysis business Veltassa® net sales impacted by reduced promotion to nephrologists due to COVID-19 Etienne Jornod stepped down as Executive Chairman; Stefan Schulze appointed [...]